<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.



                                                                  Exhibit 10.13

      THIS AGREEMENT made in duplicate as of this 14 day of June, 2004.

BETWEEN:

                                    MDS NORDION, a division of MDS (Canada) Inc.
                                    having a place of business at
                                    447 March Road
                                    Ottawa, Ontario, Canada K2K1X8

                                    ("Nordion")

AND:

                                        MOLECULAR INSIGHT PHARMACEUTICALS, INC.
                                        having a place of business at
                                        160 Second Street
                                        Cambridge Massachusetts, 02142 USA

                                        ("Molecular Insight Pharmaceuticals")

WHEREAS:

I.    Molecular Insight Pharmaceuticals is the owner or licensee of a certain
      compound known as BMIPP (as defined), a heart diagnostic imaging agent;

II.   Nordion has expertise in the development of pharmaceutical processes and
      radiolabelling of compounds;

III.  Molecular Insight Pharmaceuticals has developed techniques and
      demonstrated an ability to label Precursor with 1-123 to form BMIPP;

IV.   Molecular Insight Pharmaceuticals desires that Nordion undertake at its
      facility a development program based upon Molecular Insight
      Pharmaceutical's technique which will allow Molecular Insight
      Pharmaceuticals' Precursor to be labeled with 1-123 to form BMIPP;

V.    Molecular Insight Pharmaceuticals desires that Nordion establish a
      facility at its site in Vancouver, British Columbia, to produce and supply
      BMIPP for use in support of Molecular Insight Pharmaceuticals' Phase III
      Clinical Trials and in support of Molecular Insight Pharmaceuticals' drug
      submission to the FDA.

NOW THEREFORE in consideration of the mutual covenants and agreements herein
contained, and subject to the terms and conditions hereinafter set out, the
parties hereto agree as follows:

<PAGE>

                                       2

                             ARTICLE 1 - DEFINITIONS

For the purposes of this Agreement:

1.1   "Affiliate" shall mean an entity or person which controls, is controlled
      by or is under common control with either party. For purposes of this
      Section 1.1 control shall mean (a) in the case of corporate entities, the
      direct or indirect ownership of more than one-half of the stock or
      participating shares entitled to vote for the election of directors, and
      (b) in the case of a partnership, the power to direct the management and
      policies of such partnership.

1.2   "BMIPP" shall mean a pharmaceutical product containing 1-123 labeled
      Precursor in diagnostic dosage form for cardiac imaging.

1.3   "Background Technology" shall mean all Nordion proprietary technology
      existing prior to the Effective Date, including patents, copyright,
      know-how, techniques, methods, processes and trade secrets which Nordion
      owns or which is licensed to Nordion and, in each case, which is in
      existence in the form of a writing, prototype or can otherwise be
      demonstrated to be the property of Nordion prior to the Effective Date.

1.4   "Batch" shall mean a production batch of BMIPP manufactured under this
      Agreement.

1.5   "Clinical Trial Batch Size" shall have the meaning attributed in Section
      4.1.

1.6   "Clinical Trials" shall mean Phase III human trials for clinical
      development of BMIPP in the United States.

1.7   "Commercial Phase" shall mean the period of supply of BMIPP commencing
      after NDA regulatory approval has been received in the United States by
      Molecular Insight Pharmaceuticals, from the FDA.

1.8   "Current Good Manufacturing Practices" or "cGMP(s)" shall mean the good
      manufacturing practices required by the FDA and as set forth in the FD&C
      or FDA rules and regulations for the manufacturing, testing and quality
      control of pharmaceutical materials as applied to compounds, which
      practices are current on the Effective Date of this Agreement and may be
      supplemented, amended or modified from time to time.

1.9   "Development Phase" shall mean the period commencing from the Effective
      Date until completion of the activities described in Schedule A.

1.10  "Effective Date" shall mean the date first above written.
<PAGE>
                                        3

1.11  "FDA" shall mean the United States Food and Drug Administration.

1.12  "FD&C" shall mean the United States Federal Food, Drug and Cosmetic Act,
      as amended.

1.13  "Facility" shall mean the facility to be established by Nordion at its
      manufacturing site in Vancouver, British Columbia as described in Schedule
      B and pursuant to cGMPs, to be used for the production of BMIPP for
      diagnostic applications and purposes.

1.14  "IND" shall mean an Investigational New Drug Application as defined by the
      rules and regulations promulgated under the FD&C and U.S. Public Health
      Service Act and any supplements, modifications or amendments thereunder.

1.15  "Isotope" or "I-123" shall mean Iodine 123.

1.16  "Master Validation Plan" shall mean the program mutually agreed to by the
      parties by which documented evidence provides assurance that the Process
      will consistently produce BMIPP that meets Specifications.

1.17  "NDA" shall mean a new drug application as defined in the rules and
      regulations promulgated under the FD&C and U.S. Public Health Service Act,
      as supplemented, modified or amended from time to time.

1.18  "Precursor" shall mean (beta)-methyl-p-iodophenyl-pentadecanoic acid
      specified in Schedule C and produced pursuant to cGMPs.

1.19  "Process" shall mean the method of formulation, dispensing, and testing of
      the BMIPP developed under this Agreement and in compliance with cGMPS.

1.20  "Reference Standards" shall mean the cGMP compliant compounds as specified
      in Schedule D.

1.21  "Specification(s)" shall mean those final specifications for BMIPP as set
      out in Schedule E, as amended by mutual agreement of the parties from time
      to time.

                              ARTICLE 2 - PURPOSE

2.1   Scope and Object

      The scope and object of this Agreement is to carry out the development of
      the Process in accordance with the responsibilities and obligations
      attributed to each of the parties as set out in this Agreement. In
      addition,

<PAGE>

                                        4

      this Agreement shall provide for the establishment of a Facility to be
      utilized, amongst other purposes, in the production and supply of BMIPP as
      required in support of Molecular Insight Pharmaceuticals' BMIPP Phase III
      Clinical Trial and NDA submission to the FDA.

                         ARTICLE 3 - DEVELOPMENT PHASE

3.1   Development Activities

      During the Development Phase, Nordion and Molecular Insight
      Pharmaceuticals shall carry out their respective obligations described and
      attributed in Schedule A, it being understood that some activities may be
      reasonably delayed to the extent that such activity is premised on the
      work or provision of data, information or technology by the other party.
      It is understood and acknowledged that due to the developmental nature of
      the activities to be carried out during the Development Phase, the time
      for completion and sequence for carrying out the activities as set out in
      Schedule A shall serve as a guide. Each party shall use their commercially
      reasonable best efforts in order to carry out, in a timely manner, their
      respective obligations and responsibilities set out in Schedule A.

      If either party, acting in good faith, materially fails to satisfy any
      milestone or is unable to meet such milestone in accordance with the
      timing set out in Schedule A, such party shall provide written notice
      thereof to the other party and the parties shall determine a reasonable
      corrective action plan and revised milestone schedule. If the parties are
      unable to determine a reasonable corrective action plan and revised
      milestone schedule, the parties may submit such matter to binding
      arbitration in Vancouver, British Columbia, pursuant to and conducted
      under the International Commercial Arbitration Act of British Columbia,
      which arbitration shall be conducted before a single arbitrator possessing
      appropriate industry experience as selected by the parties. If the parties
      cannot agree on a single arbitrator, the arbitrator shall be appointed in
      accordance with the International Commercial Arbitration Act of British
      Columbia. The decision of the arbitrators shall be final and binding.

      The parties acknowledge and agree that Schedule A may be amended during
      the course of the Development Phase to accommodate unforeseen events and
      results. All such changes to Schedule A shall be made by written agreement
      of the parties. If any change to Schedule A materially impacts the scope
      of work to be provided by Nordion, Nordion will provide a written estimate
      of the increase in hours of work at the rates set forth in Section 6.3,
      which must be approved in advance by Molecular Insight Pharmaceuticals. No
      work on such scope change shall be carried out by

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.



                                       5

      Nordion prior to Nordion's receipt of Molecular Insight Pharmaceuticals'
      written approval of such change.

      The parties, upon signing this Agreement, shall each designate a program
      manager, who shall be responsible for coordinating communication and
      monitoring performance under this Agreement. The program managers shall
      meet monthly, in person or by telephone, for the purpose of reviewing the
      status of the project, assessing progress against the milestones and
      activities set forth in Schedule A, and determining the percentage of each
      milestone completed and the payments earned, if any, in connection with
      each milestone. Minutes of meetings shall be prepared, maintained and
      provided to each of the parties.

3.2   Development Phase Work

      In consideration of Nordion performing the Development Phase services,
      Molecular Insight Pharmaceuticals shall pay Nordion in accordance with the
      rates set out in Schedule F, which schedule includes amounts payable upon
      achievement of milestones as well as amounts payable for each Batch
      produced and supplied by Nordion hereunder. All amounts due Nordion shall
      be paid by Molecular Insight Pharmaceuticals within thirty (30) days of
      the date appearing on Nordion's invoice. Such invoice shall, unless
      otherwise agreed, be payable in United States dollars.

3.3   Facility Program

      In consideration of Nordion establishing the Facility, Molecular Insight
      Pharmaceuticals will pay to Nordion a non-reimbursable facility fee of
      [**********************] United States dollars (US $[********]) upon
      execution of this Agreement.

      After the Facility is completed, Nordion shall, in consultation with
      Molecular Insight Pharmaceuticals, develop and implement a Master
      Validation Plan for the Facility that will allow the production of BMIPP
      under cGMPs in the volumes required by Molecular Insight Pharmaceuticals
      for Phase III clinical supply as described in Section 4.1. The costs of
      preparation, development and implementation of the Master Validation Plan
      will be borne by Nordion. Prior to implementation, both parties shall in
      writing approve the Master Validation Plan. Nordion shall ensure that the
      Facility is available for the production of BMIPP for supply to Molecular
      Insight Pharmaceuticals on a priority basis at least three days per week
      to be mutually agreed between the parties.

3.4   Repairs and Maintenance

<PAGE>

                                        6

      After the Facility is established, Nordion shall maintain such Facility in
      satisfactory operating condition as required by the Specifications,
      Process and cGMPs, and all other applicable laws, regulations, rules or
      orders. The cost of repairs, preventive maintenance and service contracts
      for the Facility shall be borne by Nordion.

3.5   Commercial Phase Negotiations

      Within thirty (30) days after completion of Milestone 2 under the
      Development Phase, the parties shall for a period of at least sixty (60)
      days enter into good faith negotiations for the supply of BMIPP to
      Molecular Insight Pharmaceuticals, during the Commercial Phase.

              ARTICLE 4 - BATCH SIZE IN SUPPORT OF NDA SUBMISSION

4.1   Clinical Supply Batch Size

      The Batch size for Clinical Trial supply shall be thirty (30) doses of
      BMIPP. The maximum number of vials available for shipment from any Batch
      will be twenty (20) doses with the remainder being retained by Nordion for
      archival and quality assurance testing. BMIPP will be shipped in an
      appropriate lead shield, which will be provided at Nordion's expense. All
      necessary labels for shipment will be provided by Molecular Insight
      Pharmaceuticals and shall meet all applicable regulatory requirements.


                       ARTICLE 5 - GENERAL MANUFACTURE AND
                         SUPPLY OBLIGATIONS OF NORDION

5.1   BMIPP Supply

      Nordion agrees to (i) use the Process to produce Batches of BMIPP that
      meet the Specifications and are manufactured in conformance with cGMPs and
      (ii) ship BMIPP to customers as directed by Molecular Insight
      Pharmaceuticals. Nordion reserves the right to withhold from shipment any
      Batch which does not conform to Specifications. The price of any Batch
      required by Molecular Insight Pharmaceuticals during the term of this
      Agreement shall be as set out in Schedule F. The parties agree that
      Molecular Insight Pharmaceuticals will provide BMIPP at its expense and
      Nordion will supply isotopes and other supplies at its expense.

5.2   Compliance with Law; Handling of BMIPP

      While Precursor, Isotope and BMIPP are in its possession or under its
      control, Nordion shall be responsible for compliance with applicable
      statutory and regulatory requirements in the United States and Canada
      regarding the development, manufacture, handling, storage, labeling,

<PAGE>

                                        7

      packaging, transportation and shipment of the Precursor, Isotope and
      BMIPP.

5.3   Testing and Documentation

      Nordion shall maintain accurate and complete production records with
      respect to the Process, Batches and shipments and Molecular Insight
      Pharmaceuticals shall have access to such records in order to determine
      that each Batch was produced and tested in compliance with the
      Specifications and cGMP requirements.

      The tests and analyses provided in the Specifications as well as the
      nature and form of records may be amended by Nordion from time to time,
      subject to the consent of Molecular Insight Pharmaceuticals, which shall
      not be unreasonably withheld after Nordion shall have delivered to
      Molecular Insight Pharmaceuticals, in writing, an explanation of such
      changes and why they are necessary or advisable.

                               ARTICLE 6 - GENERAL
                  MOLECULAR INSIGHT PHARMACEUTICALS OBLIGATIONS

6.1   Precursor and Reference Standards

      Molecular Insight Pharmaceuticals or, at Molecular Insight
      Pharmaceuticals' discretion its designee, shall provide Precursor and
      Reference Standards to Nordion at no charge, which meets the
      specifications in Schedules C and D in sufficient quantities to permit
      Nordion to meet its obligations hereunder. Nordion shall only use
      Precursor and Reference Standards for the manufacture of BMIPP pursuant to
      this Agreement. Nordion shall store Precursor and Reference Standards in
      accordance with its applicable specifications set out in Schedule C and D
      respectively. Molecular Insight Pharmaceuticals shall at all times retain
      title in and to such materials in Nordion's possession.

6.2   Unavailability or Scarcity of Precursor or Reference Standards

      Molecular Insight Pharmaceuticals will notify Nordion upon Molecular
      Insight Pharmaceuticals becoming aware of a shortage of supply of
      Precursor or Reference Standards, if such shortage will impact the
      manufacture of the BMIPP. Except as set out below, Molecular Insight
      Pharmaceuticals shall not be liable for any delays or shortages in the
      supply of Precursor or Reference Standards, provided however, that any
      such shortages or delays in Precursor or Reference Standards supply will
      excuse Nordion's performance of activities related to such Batch of BMIPP
      only to the extent that Nordion's non-performance was caused by the

<PAGE>
                                       8

      Precursor or Reference Standards supply delay or shortage and only for a
      period of time equal to the delay.

6.3   Additional Compensation to Nordion

      In addition to the amounts set forth in Schedule F, Molecular Insight
      Pharmaceuticals will compensate Nordion based on the rate of one hundred
      and twenty-five United States dollars (US$125.00) per person per hour for
      the time spent by Nordion on the following activities only and upon
      Molecular Insight Pharmaceuticals prior written request:

      (i)   preparing and hosting Facility audits requested by Molecular Insight
            Pharmaceuticals including FDA preaudit inspections;

      (ii)  preparing responses to FDA inquiries and preparation by Nordion of
            information requested by Molecular Insight Pharmaceuticals in
            support of Molecular Insight Pharmaceuticals' BMIPP NDA submission;
            and

      (iii) attending meetings with the FDA.

      Molecular Insight Pharmaceuticals shall reimburse Nordion for all costs
      incurred for travel and accommodation in carrying out the foregoing
      activities. Nordion shall provide an estimate of all such activities to
      Molecular Insight Pharmaceuticals prior to incurring the expenditure.


                          ARTICLE 7 - BMIPP SHIPMENTS

7.1   Orders and Shipments

      During the term of this Agreement, Molecular Insight Pharmaceuticals will
      forward orders to Nordion at its Kanata, Ontario facility by facsimile.
      Each order will set forth the quantity to be produced and shipped, the
      identity of the recipient, delivery destination protocol number, IND
      number, applicable USNRC materials license number and IRS number. Delivery
      of BMIPP to Molecular Insight Pharmaceuticals or as otherwise directed by
      Molecular Insight Pharmaceuticals shall be FOB transport vehicle at
      Nordion's facility in Vancouver, British Columbia. Risk of loss of BMIPP
      shall pass to Molecular Insight Pharmaceuticals at point of delivery.

      During the term of this Agreement Nordion shall use commercially
      reasonable best efforts to meet Molecular Insight Pharmaceuticals' orders
      and delivery requirements. Prior to the first shipment of BMIPP to any
      third party site, Molecular Insight Pharmaceuticals shall obtain from such
      third party and provide to Nordion such third party's license evidencing
      proper legal authority for the receipt and possession of the BMIPP by such
      third party. Molecular Insight Pharmaceuticals shall obtain all approvals,
      licenses and permits required to import BMIPP into the United States.
<PAGE>

                                        9

      Nordion shall make shipping arrangements with AirNet Express or such other
      carrier designated by Nordion and reasonably approved by Molecular Insight
      Pharmaceuticals. All shipping costs incurred to deliver BMIPP shall be
      borne by Molecular Insight Pharmaceuticals.

      Molecular Insight Pharmaceuticals shall be entitled to cancel any Batch
      ordered from Nordion by providing to Nordion at least two (2) business
      days written notice of cancellation prior to the later of commencement of
      production or the scheduled production date. The failure to give notice
      hereunder shall result in Molecular Insight Pharmaceuticals being required
      to pay the full purchase price of such Batch to Nordion. All orders for
      BMIPP shall be forwarded by Molecular Insight Pharmaceuticals and received
      by Nordion by the Friday Noon (Eastern time) prior to the week in which
      BMIPP is to be manufactured.

7.2   Warranty/Recall

      Nordion warrants the BMIPP will meet the Specifications and be
      manufactured in accordance with cGMP's and be free from defects in
      material and workmanship for the period from the date of manufacture to
      the expiry date set out on each vial of BMIPP.

      If either party discovers that a Batch of BMIPP does not meet the
      Specifications, then the discovering party shall promptly communicate with
      the other party. If Molecular Insight Pharmaceuticals determines that the
      failure to meet Specifications results from an act, failure to act or
      other fault of Nordion, or agent of Nordion, Nordion will promptly:

      (i) repair or replace such batch of BMIPP; and

      (ii) pay for shipping costs of replacement of BMIPP.

      In the event that Nordion disputes Molecular Insight Pharmaceuticals'
      determination that the fault id due to Nordion and/or its agent, the
      parties will select a mutually acceptable outside consulting firm which
      will be instructed to review the applicable information and data and
      confirm or dissent from Molecular Insight Pharmaceuticals' determination.
      If the consulting firm confirms Molecular Insight Pharmaceuticals'
      determination, Nordion will have the obligations set out in this Section
      and Nordion will pay the fees of such consulting firm. If the consulting
      firm dissents from Molecular Insight Pharmaceuticals' determination or
      determines that the failure to meet Specifications was due to products,
      information or services supplied by Molecular Insight Pharmaceuticals,
      Nordion will not have the obligations set out in this Section with respect
      to the disputed Batch and Molecular Insight Pharmaceuticals will pay the
      fees for such consulting firm.

<PAGE>

                                       10

                               ARTICLE 8 - LICENSE

8.1   Royalty-Free License

      Molecular Insight Pharmaceuticals hereby provides to Nordion a
      nonexclusive, nontransferable, royalty-free license during the term of
      this Agreement to use the patents, data, information and technology
      provided by Molecular Insight Pharmaceuticals relating to BMIPP and the
      radiolabelling of 1-123 with Precursor for the sole purpose of assisting
      Nordion in carrying out its obligations set out in this Agreement.
      Molecular Insight Pharmaceuticals represents and warrants that the
      technology provided by Molecular Insight Pharmaceuticals relating to BMIPP
      allows for BMIPP to be terminally sterilized while still meeting the
      specifications set out in Schedule E.

                  ARTICLE 9 - MOLECULAR INSIGHT PHARMACEUTICALS
                         REPRESENTATIONS AND WARRANTIES

9.1   Molecular Insight Pharmaceuticals' Representations and Warranties

      Molecular Insight Pharmaceuticals represents, warrants and covenants that:

      (i)   it has full right, power and authority to enter into this Agreement;

      (ii)  it is the owner or has the right of use of the patents, data,
            information and technology supplied to Nordion by Molecular Insight
            Pharmaceuticals to assist Nordion in manufacturing BMIPP and in
            carrying out its obligations hereunder;

      (iii) to Molecular Insight Pharmaceuticals' knowledge, there is no action
            or proceeding pending or threatened against Molecular Insight
            Pharmaceuticals before any court, administrative agency or other
            tribunal which might have an adverse material effect on its ability
            to perform its obligations hereunder;

      (iv)  it has the right to grant the license in section 8.1 and right to
            permit Nordion to use the patents, technology and know how provided
            to the extent required to assist Nordion in carrying out its
            obligations under this Agreement;

      (v)   it has not received any notice of adverse claim or infringement of
            any patent, copyright, or misappropriation of trade secrets in
            connection with the use and exploitation of the Precursor, Reference
            Standard or BMIPP;

      (vi)  to Molecular Insight Pharmaceuticals' best information and belief,
            use or sale of Precursor, Reference Standards and BMIPP and the
            data, information, technology and know how used in the Process and
            manufacture of BMIPP contributed by Molecular Insight
            Pharmaceuticals do not infringe any valid third party patent,

<PAGE>

                                       11

            pending published patent application or other intellectual property
            right.

              ARTICLE 10 - NORDION'S REPRESENTATIONS AND WARRANTIES

10.1  Representations and Warranties

      Nordion represents, warrants and covenants that:

      (i)   it has full right and authority to enter into this Agreement;

      (ii)  it is the owner or has the right to use the data, information and
            technology contributed by it with respect to the Background
            Technology and other proprietary technology contributed by Nordion
            during the Agreement;

      (iii) the Background Technology contributed by Nordion does not, to
            Nordion's best information and belief, infringe any patents,
            copyright or other industrial or intellectual property rights of
            third parties;

      (iv)  it has not received any notice of adverse claim of infringement of
            any patent or misappropriation of trade secrets in connection with
            the use and exploitation of the data, information and technology
            used with respect to Background Technology contributed by Nordion;
            and

      (v)   to Nordiont's knowledge, there is no action or proceeding pending or
            threatened against Nordion before any court, administrative agency
            or other tribunal which might have a adverse material effect on
            Nordion's ability to perform its obligations hereunder.

                             ARTICLE 11 - INDEMNITY

11.1  Indemnification by Molecular Insight Pharmaceuticals

      Molecular Insight Pharmaceuticals agrees to indemnify, defend and hold
      Nordion and its Affiliates and their respective directors, officers,
      employees and agents, harmless from and against any damages, claims,
      liabilities and expenses (including, but not limited to, reasonable
      attorney's fees) resulting from any third party claims or suits ("General
      Claims Against Nordion") arising out of (a) Molecular Insight
      Pharmaceuticals' or a third party's use, handling or shipment of Reference
      Standards, Precursor or BMIPP, (b) Molecular Insight Pharmaceuticals'
      breach of any of its obligations, warranties or representations hereunder,
      or (c) Molecular Insight Pharmaceuticals' negligent acts or omissions or
      willful misconduct. Notwithstanding the foregoing, Molecular Insight
      Pharmaceuticals will not be required to indemnify, defend and hold Nordion
      and its Affiliates and their respective directors, officers, employees and
      agents harmless from and against any General Claims Against Nordion to the
      extent that such claims arise out of (i) Nordion's

<PAGE>

                                       12

      breach of any of its obligations, warranties or representations hereunder;
      (ii) Nordion's negligent acts or omissions or willful misconduct; (iii)
      any failure of Nordion to manufacture, handle, store, label, package,
      transport or ship BMIPP in accordance with this Agreement, cGMPs or any
      other applicable laws, rules, regulations or other requirements of any
      applicable governmental entity; or (iv) any failure of Nordion to
      manufacture BMIPP consistent with the Specifications and requirements set
      forth herein or with the applicable sections of Molecular Insight
      Pharmaceuticals' IND in the United States. Notwithstanding anything in
      this Section 11.1, "General Claims Against Nordion" shall not include "IP
      Claims Against Nordion" as described in Section 11.3.

11.2  Indemnification by Nordion

      Nordion agrees to indemnify, defend and hold Molecular Insight
      Pharmaceuticals and its Affiliates and their respective directors,
      officers, employees and agents, harmless from and against any damages,
      claims, liabilities and expenses (including, but not limited to,
      reasonable attorney's fees) resulting from any third party claims or suits
      ("General Claims Against Molecular Insight Pharmaceuticals") arising out
      of (a) Nordion's manufacture, handling, storage, labeling, packaging or
      delivery of the BMIPP; (b) Nordion's breach of any of its obligations,
      warranties or representations hereunder; (c) Nordion's negligent acts or
      omissions or willful misconduct; (d) any failure of the BMIPP to meet the
      Specifications; or (e) any failure of Nordion to manufacture, handle,
      store, label, package, transport or ship BMIPP in accordance with this
      Agreement or cGMPs or any other applicable laws, regulations or other
      requirements of any applicable governmental entity. Notwithstanding the
      foregoing, Nordion will not be required to indemnify, defend and hold
      Molecular Insight Pharmaceuticals and its Affiliates and their respective
      directors, officers, employees and agents harmless from and against any
      General Claims Against Molecular Insight Pharmaceuticals to the extent
      that such claims arise out of (i) Molecular Insight Pharmaceuticals'
      breach of any of its obligations, warranties or representations hereunder;
      (ii) Molecular Insight Pharmaceuticals' negligent acts or omissions or
      willful misconduct; (iii) any defect or failure of Reference Standards or
      Precursor to meet applicable specifications or (iv) Molecular Insight
      Pharmaceuticals' or third party's use of BMIPP. Notwithstanding anything
      in this Section 11.2, "General Claims Against Molecular Insight
      Pharmaceuticals" shall not include "IP Claims Against Molecular Insight
      Pharmaceuticals" as described in Section 11.4.

11.3  Intellectual Property Claims Against Nordion

      Molecular Insight Pharmaceuticals agrees to indemnify, defend and hold
      Nordion and its Affiliates and their respective directors, officers,

<PAGE>

                                       13

      employees and agents, harmless from and against any damages, claims,
      liabilities and expenses (including, but not limited to, reasonable
      attorneys' fees) resulting from any third party claims or suits arising
      out of any proceeding instituted by or on behalf of a third party based
      upon a claim that the Process, method of manufacture, use or sale of the
      Reference Standards, Precursors or BMIPP infringes a United States or
      Canadian patent or any other intellectual property or proprietary right of
      a third party ("IP Claims Against Nordion"). Notwithstanding the
      foregoing, to the extent the Process or method of manufacture is developed
      or contributed by Nordion, Molecular Insight Pharmaceuticals will not be
      required to indemnify, defend or hold harmless Nordion or its Affiliates,
      and their respective directors, officers, employees and agents from and
      against IP Claims Against Nordion.

11.4  Intellectual Property Claims Against Molecular Insight Pharmaceuticals

      Nordion agrees to indemnify, defend and hold harmless Molecular Insight
      Pharmaceuticals and its Affiliates, and their respective directors,
      officers, employees and agents from and against any damages, claims,
      liabilities and expenses (including, but not limited to, reasonable
      attorney's fees) resulting from any third party claims or suits arising
      out of any proceeding instituted by or on behalf of a third party based
      upon a claim that the Background Technology, the method of manufacture of
      BMIPP or the Process, to the extent developed or contributed by Nordion,
      infringes a United States or Canadian patent or any other intellectual
      property or proprietary right of a third party ("IP Claims Against
      Molecular Insight Pharmaceuticals").

11.5  Infringement

      In the event that any portion of the Background Technology or technology
      developed or contributed by Nordion under this Agreement becomes the
      subject of a claim for a patent, copyright or other industrial or
      intellectual property rights infringement action by a third party, Nordion
      may,

      (i)   if such technology was contributed by Nordion, procure the right to
            continue using the radiolabelling technology within a reasonable
            time not to exceed sixty (60) days; or

      (ii)  modify the Process (to the extent developed or contributed by
            Nordion) to become non-infringing; or

      (iii) if neither (i) nor (ii) are possible, upon written notice to
            Molecular Insight Pharmaceuticals immediately cease its activities
            and/or terminate this Agreement.

      The cost and expense of any opinion of counsel sought by Nordion under
      this section shall be borne by Nordion. Nordion reserves the right to
      control and direct the defense and/or settlement of such claim with legal
      counsel of its choosing; provided, however, that it may not settle such

<PAGE>

                                       14

      claims without the prior written consent of Molecular Insight
      Pharmaceuticals, which shall not be unreasonably withheld or delayed;
      provided, further that no such consent from Molecular Insight
      Pharmaceuticals shall be required if such settlement includes a full
      release of Molecular Insight Pharmaceuticals.

      In the event that any portion of the Process that was developed or
      contributed by Molecular Insight Pharmaceuticals becomes the subject of a
      claim for a patent, copyright or other industrial or intellectual property
      rights infringement action by a third party, Molecular Insight
      Pharmaceuticals may, (i) within a reasonable time not to exceed sixty (60)
      days procure the right to continue using the Process or technology, (ii)
      modify the Process, to the extent contributed by Molecular Insight
      Pharmaceuticals, to become non-infringing or (iii) if neither (i) nor (ii)
      are reasonably possible, Molecular Insight Pharmaceuticals may terminate
      this Agreement upon written notification to Nordion. Molecular Insight
      Pharmaceuticals reserves the right to control an direct the defense and/or
      settlement of such claims with legal counsel of its choosing; provided,
      however, that it may not settle such claims without the prior written
      consent of Nordion, which shall not be unreasonably withheld or delayed;
      provided, further that no such consent from Nordion shall be required if
      such settlement includes a full release of Nordion.

11.6  Indemnification Procedures

      A party (the "indemnitee") which intends to claim indemnification under
      this Article 11 shall promptly notify the other party (the "Indemnitor")
      in writing of any action, claim or other matter in respect of which the
      Indemnitee or any of its directors, officers, employees or agents intend
      to claim such indemnification; provided, however, the failure to provide
      such notice within a reasonable period of time shall not relieve the
      Indemnitor of any of its obligations hereunder except to the extent the
      Indemnitor is materially prejudiced by such failure. The Indemnitor shall
      be entitled to control the defense of and/or settle any such action, claim
      or other matter. The Indemnitee agrees to the complete control of such
      defense or settlement by the Indemnitor, provided, however, any settlement
      of such claims shall require the Indemnitee's prior written consent unless
      such settlement includes a full release of the Indemnitee, in which case
      no consent shall be required. The Indemnitee and its directors, officers,
      employees and agents shall co-operate fully with the Indemnitor and its
      legal representatives in the investigation and defence of any action,
      claim or other matter covered by this indemnification. The Indemnitee
      shall have the right, but not the obligation, to be represented by counsel
      of its own selection and at its own expense.

<PAGE>

                                       15

                       ARTICLE 12 - PATENTS AND TECHNOLOGY

12.1  Ownership of Work Performed

      The portion of the Process as developed or contributed by Molecular
      Insight Pharmaceuticals shall be the sole and exclusive property of
      Molecular Insight Pharmaceuticals. Except to the extent the Process is
      developed or contributed by Molecular Insight Pharmaceuticals, Molecular
      Insight Pharmaceuticals agrees and acknowledges that any and all ideas,
      technology, method, data, information, inventions, improvements,
      derivative works and works of authorship conceived, written, created or
      first reduced to practice in the performance of the development of the
      Process, Background Technology and improvements to the Background
      Technology during the term of this Agreement, shall be the sole and
      exclusive property of Nordion.

                         ARTICLE 13 - REGULATORY MATTERS

13.1  Regulatory Status

      Upon Nordion's reasonable request, Molecular Insight Pharmaceuticals shall
      provide updates to Nordion on (i) the progress of Clinical Trials related
      to BMIPP, and (ii) submissions to the FDA and other jurisdictions and
      regulatory agencies for marketing authorization with respect to BMIPP.

13.2  Molecular Insight Pharmaceuticals Responsibilities

      It shall be the responsibility of Molecular Insight Pharmaceuticals or its
      designee to file, obtain and maintain an IND, registrations, listings,
      authorizations and approvals as the FDA or any other applicable
      governmental entity may require to enable use of BMIPP in Clinical Trials
      in the United States. Nordion shall provide directly to Molecular Insight
      Pharmaceuticals, or at Nordion's discretion for the purpose of protection
      of its proprietary technology with respect to the manufacture of the
      Isotope, directly to the regulatory authority all required information in
      its possession necessary to assist Molecular Insight Pharmaceuticals in
      filing, obtaining and maintaining all licenses, registrations, listings,
      authorizations and approvals of any governmental entities necessary for
      the use of BMIPP in support of Molecular Insight Pharmaceuticals' BMIPP
      NDA submission.

13.3  Nordion Responsibilities

      Nordion shall be responsible for obtaining and maintaining all necessary
      Facility licenses, registrations, authorizations and approvals which are
      necessary to develop, manufacture, handle, store, label, package,

<PAGE>

                                       16

      transport and ship BMIPP under cGMP conditions and other regulatory
      requirements including, but not limited to, the use and handling of
      radioactive materials.

      At Nordion's expense, Nordion shall update its existing 1-123 bulk
      chemical or facility description Drug Master File ("DMF") with the FDA as
      may be required for Molecular Insight Pharmaceuticals' NDA for BMIPP in
      accordance with Schedule A. Nordion hereby grants Molecular Insight
      Pharmaceuticals a right of reference to such DMF, and upon request shall
      provide a letter of access to the DMF allowing regulatory review of the
      DMF by the FDA in conjunction with Molecular Insight Pharmaceuticals'
      BMIPP submissions. At Nordion's expense, Nordion shall apply for and seek
      a DMF for BMIPP in accordance with Schedule A.

13.4  Government Inspections, Compliance Review and Inquiries

      Upon request of any governmental entity or any third party entity
      authorized by a governmental entity, such entity shall, for the purpose of
      regulatory review, have access to observe and inspect the (i) Facility,
      (ii) procedures used for the storage of Reference Standards and Precursor,
      and (iii) manufacturing, testing, storage and shipping of BMIPP, including
      Process development operations, and auditing the Facility for compliance
      with cGMP and/or other applicable regulatory standards. Nordion shall give
      Molecular Insight Pharmaceuticals prompt written notice of any upcoming
      inspections or audits by a governmental entity of the Facility or any of
      the foregoing and shall allow Molecular Insight Pharmaceuticals to
      participate in such audits by being present at any FDA close out meeting
      and shall provide Molecular Insight Pharmaceuticals with a written summary
      of such inspection or audit following completion thereof. Nordion agrees
      to use commercially reasonable efforts to promptly rectify or resolve any
      deficiencies noted by a government entity in a report or correspondence
      issued to Nordion.

13.5  Access to the Facility

      Molecular Insight Pharmaceuticals shall have reasonable access to the
      Facility at least once per calendar quarter during the Development Phase
      for the purpose of observing Process development relating to BMIPP.
      Molecular Insight Pharmaceuticals shall provide to Nordion at least five
      (5) business days prior written notice of requested access to the Facility
      for the purpose of this Section. All such information disclosed to
      Molecular Insight Pharmaceuticals or its employees or agents, shall be
      deemed to be Nordion's Confidential Information as such term is defined in
      Section 14.1 of this Agreement.

13.6  Recalls

<PAGE>

                                       17

      Molecular Insight Pharmaceuticals shall notify Nordion promptly if BMIPP
      is the subject of a recall or correction (a "Recall"), and Molecular
      Insight Pharmaceuticals and/or its designee shall have sole responsibility
      for the handling and disposition of such Recall. Molecular Insight
      Pharmaceuticals and/or its designee shall bear the costs of any Recall of
      BMIPP unless and to the extent such Recall shall have been the result of
      Nordion's or its employees acts of omissions or any product defects for
      which Nordion is responsible in which case Nordion shall to such extent be
      responsible for all of Molecular Insight Pharmaceuticals' out-of-pocket
      costs incurred for:

      (i)   notification of recall to Nordion and third parties;

      (ii)  return shipment of any defective BMIPP to Nordion; and

      (iii) replacement of BMIPP.

      In the event that Nordion disputes Molecular Insight Pharmaceuticals'
      determination that the fault is due to Nordion and/or to its agent, the
      parties will select a mutually agreeable outside consulting firm which
      will be instructed to review the applicable information and data and to
      confirm or dissent from Molecular Insight Pharmaceuticals' determination.
      If the consulting firm confirms Molecular Insight Pharmaceuticals'
      determination, Nordion will pay the fees of such consulting firm. If the
      consulting firm dissents from Molecular Insight Pharmaceuticals'
      determination Nordion will not have the obligations set forth herein with
      respect to the Recall and Molecular Insight Pharmaceuticals will pay the
      fees of such consulting firm. Molecular Insight Pharmaceuticals and/or its
      designee shall maintain records of all sales, shipping records of BMIPP
      and customers in sufficient detail to adequately administer a Recall for
      the period of time as required by applicable regulation.

13.7  New Regulatory Requirements

      Each party shall promptly notify the other of new regulatory requirements
      of which it becomes aware which are relevant to the manufacture of BMIPP
      under this Agreement and which are required by the FDA and other
      applicable governmental entities and the parties shall confer with each
      other with respect to the best means to implement and comply with such
      requirements.

13.8  Records

      Nordion shall maintain all records necessary to evidence compliance with
      (i) all applicable laws, regulations and other requirements of applicable
      governmental entities in the United States and Canada relating to the
      supply and manufacture of BMIPP; (ii) the Specifications; and (iii)
      obligations under this Agreement. All such records shall be maintained by

<PAGE>

                                       18

      Nordion for at least two (2) years after termination or expiration of this
      Agreement. Nordion shall provide to Molecular Insight Pharmaceuticals
      reasonable access to such records upon request. Prior to destruction of
      any record after such time, Nordion shall give written notice to Molecular
      Insight Pharmaceuticals. Molecular Insight Pharmaceuticals shall have the
      right to request that Nordion maintain such records in an off site storage
      facility for such longer periods as Molecular Insight Pharmaceuticals
      requests, provided that Molecular Insight Pharmaceuticals pays all costs
      associated with such off site storage.

                          ARTICLE 14 - CONFIDENTIALITY

14.1  Confidentiality and Exceptions

      During the term of this Agreement and for a period of ten (10) years
      thereafter, each party hereto shall maintain in confidence the content of
      the transactions contemplated herein, all technology including Background
      Technology and improvements thereto, Nordion proprietary technology,
      Molecular Insight Pharmaceuticals proprietary technology, trade secrets,
      know-how, data, processes, methods, techniques, formulas and test data
      (collectively "Confidential Information") and other information disclosed
      to such party by the other party which is identified as "Confidential
      information" by the disclosing party. This obligation of confidentiality
      shall not apply to the extent that it can be established by the party in
      receipt of such information, that the information:

      (i)   was already known to the receiving party at the time of disclosure;

      (ii)  was generally available to the public or otherwise part of the
            public domain at the time of its disclosure;

      (iii) became generally available to the public or otherwise part of the
            public domain after its disclosure to the receiving party through no
            act or omission of the receiving party;

      (iv)  was disclosed to the receiving party by a third party who was not
            known or ought to be known to the receiving party to have
            obligations restricting disclosure of such information; or

      (v)   was independently developed by the receiving party without any use
            of Confidential Information of the disclosing party.

      Each party agrees that it will take the same steps to protect the
      confidentiality of the other party's Confidential Information as it takes
      to protect its own proprietary and confidential information, which shall
      in no event be less than commercially reasonable steps. Each party, and
      its employees and agents shall protect and keep confidential and shall not
      use, publish or otherwise disclose to any third party, except as permitted
      by this Agreement, as necessary to perform its obligations hereunder, or

<PAGE>

                                       19

      with the other party's written consent, the other party's Confidential
      Information.

      It is agreed that disclosure of data, information or technology by
      Molecular Insight Pharmaceuticals or Nordion to the other under this
      Agreement shall not constitute any grant, option or license under any
      patent, technology or other rights, held by Molecular Insight
      Pharmaceuticals or Nordion. Any use of the data, information and
      technology provided by Molecular Insight Pharmaceuticals to Nordion which
      relates to Precursor, Reference Standards or radiolabelling of Precursor
      shall be for the limited purpose of assisting Nordion in carrying out its
      obligations under this Agreement. All data, information, or technology
      supplied by one party to the other to assist in carrying out the
      obligations hereunder shall remain the property of such party and shall be
      returned to the other party upon termination of this Agreement.

                     ARTICLE 15 - DISCLOSURE OF INFORMATION

15.1  Authorized Disclosure

      Notwithstanding section 14.1 each party may disclose Confidential
      Information to the extent such disclosure is reasonably necessary for
      prosecuting or defending litigation and/or complying with applicable
      government laws or regulations, provided that if a party is required by
      law or regulation to make any such disclosure of the other party's
      Confidential Information it will give reasonable notice to the other party
      of such disclosure requirement.

                        ARTICLE 16 - TERM AND TERMINATION

16.1  Initial Term

      The term of this agreement shall commence upon the Effective Date and,
      unless terminated earlier pursuant to this agreement, or extended upon
      mutual agreement of the parties, shall expire on December 31, 2005.

16.2  Termination Without Cause

      Molecular Insight Pharmaceuticals may terminate this Agreement without
      cause or penalty upon thirty- (30) day's prior written notice to Nordion.
      Upon such termination, Nordion shall be entitled to retain all amounts
      paid by Molecular Insight Pharmaceuticals and Molecular Insight
      Pharmaceuticals shall pay to Nordion any amounts due and/or earned but not
      yet paid.
<PAGE>

                                       20

16.3  Termination for Breach

      This Agreement may be terminated by either party in the event of the
      material breach by the other party of the terms and conditions hereof;
      provided, however, the other party shall first give to the breaching party
      written notice of the proposed termination of this Agreement (a "Breach
      Notice"), specifying the grounds therefor. Upon receipt of such Breach
      Notice, the breaching party shall have such time as necessary, but in any
      event not more than thirty (30) days to cure such breach. Notwithstanding
      the foregoing, if the breaching party does not cure such breach within
      such cure period, the other party may terminate the Agreement without
      prejudice to any other rights or remedies which may be available to the
      non-breaching party.

16.4  Bankruptcy

      This Agreement may be terminated by a party in the event the other party
      files a petition in bankruptcy, is adjudicated a bankrupt, makes an
      assignment for the benefit of its creditors, or otherwise seeks relief
      under or pursuant to any bankruptcy, insolvency or reorganization statute
      or proceeding, or if a petition in bankruptcy is filed against it which is
      not dismissed within ninety (90) days or proceedings are taken to
      liquidate the assets of such party.

                             ARTICLE 17 - SURVIVAL

17.1  Consequences or Termination or Expiration

      Upon expiration or termination of this Agreement, the obligations of the
      parties under Articles 9, 10, 11, 12, 14, 15, 19 and 24 shall survive such
      expiration or termination in accordance with its terms.

                               ARTICLE 18-NOTICES

18.1  Any notice to be sent to a party hereunder shall be forwarded to:

      Nordion at:     MDS Nordion
                      447 March Road
                      Ottawa, ON
                      K2K 1X8
      Attention:      Senior Vice President, Nuclear Medicine
                      Fax:

      Molecular Insight Pharmaceuticals at:

<PAGE>

                                       21

                      Molecular Insight Pharmaceuticals, Inc.
                      160 Second Street
                      Cambridge, MA
      Attention:      Chief Operating Officer
                      Fax: 617-492-5664

      Any notice required or authorized to be given by a party to the other in
      accordance with the provisions of this Agreement shall, unless otherwise
      specifically stipulated, be in writing and delivered personally, by a
      nationally recognized overnight courier, or if by electronic facsimile
      confirmed by certified or registered mail. Notice shall be deemed
      delivered upon receipt.

                         ARTICLE 19 - LIMITED LIABILITY

19.1  Disclaimer

      In no event shall either party be liable to the other party for indirect,
      punitive, contingent, incidental, special or consequential damages.

19.2  Limitation of Product Warranty

      MOLECULAR INSIGHT PHARMACEUTICALS ACKNOWLEDGES THAT NORDION IS
      MANUFACTURING AND SUPPLYING BMIPP TO MEET SPECIFICATIONS. EXCEPT AS
      EXPRESSLY SET OUT IN THIS AGREEMENT, NORDION HEREBY DISCLAIMS ALL OTHER
      WARRANTIES OR CONDITIONS, WHETHER EXPRESS OR IMPLIED, STATUTORY OR
      OTHERWISE, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OR
      CONDITIONS OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

                   ARTICLE 20 - ASSIGNMENT AND SUBCONTRACTING

20.1  No Assignment

      This Agreement shall enure to the benefit of and shall be binding upon the
      heirs, executors, administrators, successors and permitted assigns of the
      parties. Neither Nordion nor Molecular Insight Pharmaceuticals shall
      assign this Agreement or any portion of this Agreement without the written
      approval of the other party, which approval shall not be unreasonably
      withheld; provided, however, that Molecular Insight Pharmaceuticals may
      assign this Agreement without Nordion's consent in connection with the
      sale of all or substantially all of its stock or assets to a third party
      or in connection with a merger, consolidation or similar transaction.

                             ARTICLE 21 - COMPLIANCE

21.1  Compliance with Laws

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.



                                       22

      This Agreement and Nordion's and Molecular Insight Pharmaceuticals'
      obligations hereunder shall be carried out in compliance with all
      applicable laws, by-laws, rules, regulations and orders of all applicable
      Federal, State, Provincial and Municipal governments.

                             ARTICLE 22 - NON-WAIVER

22.1  Non-Waiver of Rights

      Failure by either party to enforce at any time any of the provisions of
      this Agreement shall not be constructed as a waiver of its rights
      hereunder. Any waiver of a breach of any provision hereof shall not be
      effective unless in writing and shall not affect either party's rights in
      the event of any additional breach.

22.2  Force Majeure

      Neither party shall be liable to the other for failure to perform or delay
      in performing its obligations under this Agreement by virtue of the
      occurrence of an event of Force Majeure. In the event of Force Majeure,
      the party affected shall promptly notify the other and shall exert
      commercially reasonable efforts to eliminate, cure or overcome such event
      and to resume performance of its obligations. In the event such Force
      Majeure affecting either party continues for more than thirty (30) days
      the party not subject of the Force Majeure may terminate this Agreement.
      "Force Majeure" shall mean an occurrence which prevents, delays or
      interferes with the performance by a party of any of its obligations
      hereunder if such event occurs by reason of any act of God, flood, power
      failure, fire, explosion, casualty or accident, or war, revolution, civil
      commotion, acts of public enemies, blockage or embargo, or any law, order
      or proclamation of any government, failure of suppliers or usually
      supplier to provide materials, equipment or machinery, interruption of or
      delay in transportation, strike or labor disruption.

                             ARTICLE 23 - INSURANCE

23.1  Product Liability Insurance

      During the term of this Agreement and for a period of one (1) year
      thereafter Molecular Insight Pharmaceuticals at its own expense shall
      provide and maintain a products liability insurance policy issued by a
      reputable insurance company with respect to BMIPP. Such policy shall add
      Nordion as an additional insured and shall have a limit of liability of
      not less than [*************] United States dollars ($[*********]US) per
      occurrence and in the aggregate. Molecular Insight Pharmaceuticals shall

<PAGE>

                                       23

      be solely responsible for any deductible or retention associated with this
      policy and such deductible or retention amounts shall not affect Nordion's
      interests. The policy shall contain a cross liability clause and shall
      provide for severability of interest such that breach of a policy
      condition committed by any one insured shall not adversely affect the
      rights of the other insured. Nordion shall be provided thirty (30) days'
      prior written notice of any material change to the policy and such change
      shall be subject to Nordion's prior written consent, which consent shall
      not be unreasonably withheld. Nothing contained in this Section shall be
      deemed to limit in any way the indemnification provisions contained in
      this Agreement.

                            ARTICLE 24 - PUBLICATION

24.1  Publicity

      The parties agree that, except as may otherwise be required by applicable
      laws, regulations, rules or orders or in connection with obtaining
      regulatory approvals for BMIPP, no information concerning this Agreement
      and the transactions contemplated herein shall be made public by either
      party without the prior written consent of the other, which consent shall
      not be unreasonably withheld or delayed. In the event either party decides
      to issue a press release announcing the execution of this Agreement, it
      shall not do so without the prior written approval of the other party.

      A copy of any proposed press release shall be provided to the other party
      for approval at least three (3) business days prior to any proposed
      release.

      In the event that this Agreement or any portion of its contents is
      required to be disclosed by Molecular Insight Pharmaceuticals or Nordion
      pursuant to Security Exchange Commission rules or regulations or other
      federal or state authorities, Molecular Insight Pharmaceuticals or
      Nordion, as the case may be, shall provide reasonable notice to the other
      prior to any such disclosure in order that, to the extent possible while
      enabling the party to comply with the applicable laws, rules and
      regulations, the content so disclosed does not include information which
      may reasonably be considered by the other as confidential, proprietary
      and/or commercially sensitive information.

                         ARTICLE 25 - DISPUTE RESOLUTION

25.1  Dispute Resolution

      Except as otherwise set out, in the event that at any time during the term
      of this Agreement, a disagreement, dispute, controversy or claim should
      arise relating to the (i) interpretation of or performance under this

<PAGE>

                                       24

      Agreement or the attribution of liability or breach thereof; or (ii)
      scientific or technical issues in connection with Nordion or Molecular
      Insight Pharmaceuticals' performance under this Agreement, the parties
      will attempt, in good faith, to resolve their differences for a period of
      thirty (30) days following written notice from one party to the other
      specifying such dispute(s). In the event the parties are unable to work
      out a resolution of the issue during such 30-day period, either party
      shall be free to take any action and seek any remedy it may have at law or
      in equity including specific performance and injunctive relief.

                       ARTICLE 26 - INDEPENDENT CONTRACTOR

26.1  No Joint Venture

      The parties agree that with respect to the transactions contemplated
      herein that they shall both be acting as independent contractors and
      nothing herein shall constitute the parties as entering into a joint
      venture or partnership, nor shall anything herein constitute either party
      as an agent of the other for any purpose whatsoever.

                            ARTICLE 27 - SEVERABILITY

27.1  Invalid Provisions

      If any provision or term of this Agreement is found unenforceable under
      any of the laws or regulations applicable thereto, all other conditions
      and provisions of this Agreement shall nevertheless remain in full force
      and effect. Upon such determination that any term or other provision is
      invalid, illegal or incapable of being enforced, the parties hereto shall
      negotiate in good faith to modify this Agreement to effect the original
      intent of the parties as closely as possible in a mutually acceptable
      manner, in order that the transaction contemplated hereby be consummated
      as originally contemplated to the greatest extent possible.

                             ARTICLE 28 - AGREEMENT

28.1  Entire Agreement

      This Agreement, including the Schedules hereto which are incorporated
      herein, constitute the entire agreement of the parties with respect to the
      subject matter hereof and supersedes all proposals, oral or written, and
      all negotiations, conversations, or discussions. This Agreement may not be
      modified, amended, rescinded, canceled or waived, in whole or in part,
      except by written amendment signed by both parties hereto.

<PAGE>

                                       25

                                ARTICLE 29 - LAW

30.1  Applicable Law

      This Agreement shall be governed and construed in accordance with the laws
      of the Province of Ontario, Canada, without reference to its principles on
      conflict of laws. The application of the United Nations Convention for the
      International Sale of Goods is expressly excluded.

<PAGE>

                                       26

      IN WITNESS WHEREOF the parties hereto have executed this agreement as of
the date first above written.

MDS Nordion,                             Molecular Insight Pharmaceuticals, Inc.
a division of MDS (Canada) Inc.

By: /s/ Gerry Vantellingen              By: /s/ John W. Babich
    ---------------------------            ------------------------

#63441 v1 - Agreement/Molecular Insight/Final
<PAGE>

                                   SCHEDULE A

                                  Scope of Work

<TABLE>
<CAPTION>
                                                                                               Commence
                                         ACTIVITY                                Duration   -------------
                                         --------                                --------    Y weeks from
                                                                                  X weeks   Effective Date
                                                                                 --------   --------------
<S>                                                                              <C>        <C>
1. Activity 1 - Technology Transfer

   a) Review Customer Supplied Documentation                                         2             1
   b) Write, review and approve Preliminary Safety Analysis Report(PSAR)             3             2
   c) Experimental Design for Scale-Up                                               2             2
   d) Scale-Up to 1 Ci (up to 10 runs maximum)
      i)   Show reproducibility of procedure                                         5             5
      ii)  Increase yield to 80% after quenching and isolation
           (commercially reasonable best efforts)

      iii) Verify autoclavability of formulation. Establish excipient
               ranges

   e) Scale up to 4 Ci (up to 5 runs)                                                3            10
   f) Document experiments and archive data (HPLC traces,                            3            13
      logbooks, etc.)
   Milestone 1 : Complete Technology Transfer                                        0            16

2. Activity 2- Reformulation and Purification

   a) Develop HPLC Separation Method                                                 6             4
   b) Develop Automation: sample transfer and collection                             4             4
   c) Develop compatibility of HPLC collected fraction with                          2             4
      Formulation. Establish excipients
   d) IQ/OQ and validate autoclave.                                                  5             4
   e) IQ/OQ/PQ for HPLC and equipment.                                               6            16
   f)  Draft Master Batch Record for Molecular Insight approval.                     2            19
   Milestone 2: Complete Reformulation and Purification                              0            21

3. Activity 3- Develop Dispensing Equipment

   a) Develop dispensing setup for 30 vial capability                               10             9
      - IQ/OQ/PQ Dispensing
      - Seal and crimp

   b) Develop container/ closure system                                              8            11
      - Complete closure test and integrity
      - Complete recoverability of dose from Container Test
   c) Establish Class 100 conditions for dispensing box at vial                      1            19
      opening.
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                  <C>          <C>
   d) IQ/OQ/PQ Shielded boxes (SB)                                                   2            20
      - calibrate gauges
      - establish airborne I-123 detection system
   e) IQ/OQ/PQ Laminar Air Flow (LAF) Assembling Area.   .                           2            20
   f) Initiate Environmental Monitoring in LAF, SB and                               3            20
      Controlled Access Room,
   Milestone 3: Complete Dispensing Equipment Development                            0            22

4. Activity 4- Develop Q.C. Test Methods

   a) HPLC Method for Final Product.                                                 4            22
      - verify                      1) BMIPP
                                    2) UDCA
                                    3) Any other identified
                                 impurities as per specifications in
                                 Schedule F.
      -   establish 1) Radiochemical Purity
                     2) Chemical purity - Quantitative method
      Note: this is a method transferred from Molecular Insight
      -   Write and approve Standard Test Method (STM)
   b) IQ/OQ/PQ Dose Calibrator                                                       2            26
       Write and Approve STM
   c) Gamma Spectroscopy                                                             1            26
      -   Calibration Protocol
      -   NIST traceability
      -   159 keV Identification (ID) for I-123
      -   Write.and approve STM
   d) Endotoxin Test (USP)                                                           1            28
      -   Dilution to overcome Inhibition/Enhancement
      -   Maximum valid dilution
      -   Qualification of test method
      -   Write and approve STM
   e) Sterility Test (USP)                                                           1            28
      -   Establish sampling size
      -   Write and approve STM
   f) Product Release Form (PRF)                                                     1            29
      -   Identify all documents necessary for batch release
   Milestone 4: Complete QC Test Methods Development                                 0            30

5. Activity 5- Validation of New Process

   a) Write and approve Master Validation Plan                                       8             4
      -    Equipment: Analytical and Process
      -    Analytical Methods
      -    Process
      -    Final Product Stability
   b) Method Transfer Validation                                                     6            30
      -    Analytical Methods
      -    References Standards (shelf-life; ID)
      -    Precursor (ID; shelf-life)
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                  <C>          <C>
   c) Validation Protocols                                                           2            36
   d) Six Process Runs to fine tune process                                          6            28
   e) Train Operators                                                                6            28
      - 3 Production technicians

      - 3 QC/QA

      - 2 Packaging
   Milestone 5: Complete Validation of New Process                                                34

6. Activity 6- Perform GMP Equivalency Run (Validation Runs)                         3            34

   a) Perform three runs (1 Ci of I-123)                                             3            37
   b) Compile all data for validation files                                          0            40
   Milestone 6: Complete Validation Runs

7. Activity 7- Prepare Development Report

   a) Document all experimentation                                                   6            31
   b) Archive all data/logbooks                                                      6            31
   c) Write and approve Development Report                                           6            39
      - Process Description and Development

      - Master Formula

      - Impurities profiles (standards to be provided by

        Molecular Insight)
      - Excipient Ranges

      - Final Product Specifications

      - Scale-Up rationale

      - Equivalence to previous formulation ( to be done in
        conjunction with Molecular Insight at their cost)

      - Qualification of Reference Standards to be done by
        Molecular Insight

      - Precursor made under cGMPs to be provided by
        Molecular Insight

      - Analytical Method and Validation to be done by
        Molecular Insight

      - Bioburden Profiles for Raw Material

      - Environmental data - house isolates

      - Molecular insight to provide stability indicating
        methods for final product

      - Define Utilities

      - Cleaning Protocol
   Milestone 7: Submit Development Report                                                         45

8. Activity 8- DMF / CMC Package

   a) Provide SOPs/STMs for CMC section of NDA                                       3            37
   b) Provide flowcharts                                                             3            37
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                  <C>          <C>
   c) Establish Review and Approval responsibility for                               3            37
      documents
   d) Establish Recall procedure                                                     3            37
   e) Establish responsibilities of                                                  3            37
      1) Deviations

      2) Change Control

      3) Product Release

      4) Failure Investigation

      5) Out-of-Spec Investigation

      6) Draft required procedures

   Milestone 8: DMF/CMC Package Complete                                                          40

9. Activity 9- Prepare for PAI

   a) audit for cGMP compliance (with customer)                                      3            40

   b) Review findings and establish action plan                                      3            40

   c) Review costs of ongoing and enhanced compliance (to be                         3            40
      billed to Molecular Insight as required)

      NOTE: PAI readiness will
      require additional staffing and/or consultants that will be charged
      to Molecular Insight.
   Milestone 9: Ready for PAI                                                                     43
</TABLE>

   Pcdocs 62635
<PAGE>

                                   SCHEDULE B

              FACILITY RESOURCES FOR CONTRACT MANUFACTURE OF BMIPP

THE FOLLOWING EQUIPMENT IS USED TO MANUFACTURE BMIPP:

-     Laminar Flow Hood for reagent and equipment preparation

-     Three Lead shielded glove boxed with HEPA filtration and Nuclear
      Ventilation

      -     Box 1 reaction, separation, formulation box containing
            semi-preparative automated HPLC for drug substance isolation

      -     Box 2 has the function to act as a dispensing area. The
            dispensing environment is class 100

      -     Box 3 is the terminal sterilization box containing an
            autoclave and a remote handling ball and tong manipulator

-     Specialized shielding assemblies are used for the safe transport of
      formulated unit dose radiopharmaceuticals

-     Fume hood with nuclear ventilation for QC analysis

-     HPLC equipment for QC analysis

-     Dose calibrator

-     Particle check station

-     Gamma Spectroscopy system

-     Refrigerator

SOME GENERAL FEATURES OF THE MANUFACTURING AREA AND SUPPORT SERVICES ARE:

-     The room is environmentally and radiation monitored

-     There are waste handling systems in place to deal with chemical waste
      streams as well as solid and liquid radioactive wastes

-     The entire manufacturing environment is cGMP regulated

-     Qualified and trained staff with experience in diagnostic
      radiopharmaceutical manufacture are employed

-     The entire manufacturing facility is supported by a calibration department

-     A fully outfitted microbiology lab is available for microbiological and
      environmental tests (Most importantly LAL tests for pyrogenicity)

-     There is an attached microbiology clean room used for sterility tests and
      filtration.

-     This clean room contains a class 100 glove box.

NOTE: EQUIPMENT OTHER THAN THAT LISTED ABOVE (SUCH AS HOT CELLS ETC.) MAY BE
USED DURING DEVELOPMENT

<PAGE>

                                   SCHEDULE C

                         BMIPP PRECURSOR SPECIFICATIONS

Note: 1. Supplied by Molecular Insight Pharmaceuticals and MDS Nordion to do
identification only

<PAGE>

                                   SCHEDULE D

                       REFERENCE STANDARDS SPECIFICATIONS

Note: 1. Supplied by Molecular Insight Pharmaceuticals and MDS Nordion to do
identification only

<PAGE>


                               SPECIFICATION SHEET

TCI America, 9211 N Harborgate St,
Portland, OR 97203                 Version Date 3/7/02      Form No. :SS. 057.02

Material            BMIPP (INACTIVE COMPONENT/PRECURSOR)         Code No.: Z3398

Formula: C(22)H(35)IO(2)       Molecular Wt.: 458.42        CAS No.: 116754-87-1

Synonym(s):  15-(p-Iodophenyl)-
3-methylpentadecanoic Acid                     Storage Conditions:<or=4C(degree)

<TABLE>
<CAPTION>
Frequency             Test                                 Acceptance Criteria                        Test Procedure
------------------    ----------------------------------   ---------------------------------------    -----------------------
<S>                   <C>                                  <C>                                        <C>
0,3,6,9, 12,          Appearance                           Colorless or white crystals or powder      SLT QC 339
18,24,36,
48, 60mo

0-60 months           Identification              FTIR     Identical to reference standard            SLT QC 327

After manufacture                                 UV-VIS   Identical to reference standard            SLT QC 371

0 - 60 months                                     HPLC     Retention time corresponds with that of    SLT QC 358
                                                           the reference standard within +/- 3%

0-60 months           Purity Assay (HPLC)                  > or = 95%                                 SLT QC 358

After manufacture     Purity, Melting point                51-56(degree)C                             SLT QC 322

After manufacture     Purity, Water analysis (KF)          Report results                             SLT QC 329

0 - 60 months         Impurities, HPLC Related             < or = 2.0 % any single species            SLT QC 358

0 - 60 months         Methyl 15-(p-Iodophenyl)-3           < or = 0.1%                                SLT QC 358
                      Methylpentadecanoate

After manufacture     Heavy metals                         < or = 20 ppm                              SLT QC 332 (Method II)

After manufacture     Residual Solvents

                                   Hexane                  < or = 290 ppm                             SLT QC 340

                                   Methanol                < or = 3000 ppm                            SLT QC 340

                                   Ethyl Acetate           < or = 5000 ppm                            SLT QC 340

                                   Ethanol                 < or = 5000 ppm                            SLT QC 340

                                   Isopropanol             < or = 5000 ppm                            SLT QC 340
After manufacture     Organic Volatile Impurities

                                   Methylene Chloride      < or = 500 ppm                             SLT QC 340
</TABLE>

<PAGE>

                                   SCHEDULE E

                              BMIPP SPECIFICATIONS
<PAGE>

SPECIFICATION SHEET                                                 Page 1 of 1

                        DRUG PRODUCT SPECIFICATION SHEET

<TABLE>
<S>                                                  <C>                <C>
Molecular Insight, 160 Second ST, Cambridge, MA      Version Date       (ACTIVE COMPONENT)
02142                                                 4/13/04
</TABLE>

Material                          [(123)I]-BMIPP              CODE NO.: MIP 1000

Formula: C(22)H(35)IO(2)           Molecular Wt.: 454.42    CAS No.: 116754-87-1

Synonym(s):   [(123)I]-15-(p-Iodophenyl)-3-methylpentadecanoic Acid

<TABLE>
<CAPTION>
            TEST                  ACCEPTANCE CRITERIA          TEST METHOD                TESTING SCHEDULE
<S>                        <C>                                 <C>                        <C>
Appearance                     Clear, Colorless Solution       Visual observation         Test Completed prior
                                                               STM 12                     to release of drug
Radionuclide Identity      Gamma-Photon emission at 159 +/-    Gamma ray Spectroscopy,    Test Completed prior
                            5 keV                              STM 23
                                                                                          to release of drug
Radionuclide Impurity      <or= 2.5% I-125 at TOC              Gamma ray Spectroscopy,    Confirmation Test of
                           <or= 110 (mu)Ci/mL I-125 at TOC     STM 21                     component Nal, After
                                                                                          decay of I-123, 2
                                                                                          weeks after release
Radioactivity                     3.6 to 4.4 mCi/mL            Dose Calibrator            Test Completed prior
Concentration                                                  STM 27                     to release of drug
Radiochemical Identity*       R(r) value between 0.30 to       Normal phase TLC           Test Completed prior
                              0.50
                                                               STM 16                     to release of drug
Radiochemical Purity            >95% as I-123-BMIPP            Reverse phase HPLC         Test Completed prior
                                                               Radiometric detector       to release of drug
                                                               STM 17
Chemical Concentration            0.36 to 0.44 mg/ml           Reverse phase HPLC         Test Completed prior
                                                               UV-VIS detector            to release of drug
                                                               STM 17
Radiochemical Impurity         <or= 5% as free I-123           Reverse phase HPLC         Test Completed prior
                                                               Radiometric detector       to release of drug
                                                               STM 17
Radiometric Assay for       4.5 to 5.5 mCi per (1.25 mL)       Dose Calibrator            Test Completed prior
unit dose vial              at TOC
Osmolarity                                                     STM 11                     to release of drug
                                Ratio to Saline 0.8 to         Osmometer, compare with    Test Completed prior
                                  1.0                          normal saline
                                                               STM 18                     to release of drug

pH                                 Range 8.2 to 9.2            pH paper                   Test Completed prior
                                                               STM 19                     to release of drug
Bacterial Endotoxin        <or=4.0 EU/ml                       Limulus Amebocyte Lysate
                                                               test on diluted drug
                                                               product                    Test Completed prior
                                                               STM 14                     to release of drug

Sterility                  No turbidity or growth              2 week incubation in       Test initiated
                                                               Fluid Thioglycollate       within 24 hours of release
                                                               Medium &
                                                               Trypticase Soy Broth
                                                               STM 13
Package Inspection         No damage                           Visual                     Test Completed prior
                                                               STM 15                     to release of drug
</TABLE>

Note: All STM numbers will be changed to equivalent MDS Nordion document
numbers.

* This TLC test may be replaced by HPLC.

TOC = Time of Calibration; 1500 h PT, one day after manufacture

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.



                                PRICE SCHEDULE F

1.    FACILITY ESTABLISHMENT FEE:

      This is a one-time fee for the establishment of the facility described in
      Schedule B.

      PRICE: $[*******] US

      Note: Fee is payable upon signing of the Agreement

2.    MILESTONES PAYMENTS:

<TABLE>
<CAPTION>
   MILESTONE                   DESCRIPTION                  PRICE US$
   ---------                   -----------                  ---------
<S>                  <C>                                    <C>
Milestones 1 & 2     Technology Transfer &                  $[*******].
                     Reformulation and Purification

Milestone 3          Dispensing Equipment                   $[*******].

Milestone 4          QC Test Methods                        $[******].

Milestone 5          Validation of New Process              $[*******].

Milestone 6          GMP Validation Runs                    $[******].

Milestone 7          Development Report                     $[******].

Milestone 8          DMF/CMC Package for                    $[******].
                     BMIPP

Milestone 9          Prepare for PAI                       Not included at this
                                                     time - estimated $[******].
</TABLE>

      Notes - [***] of each Milestone payment is due upon signing of the
      Agreement, [***] when the specific Milestone is commenced and the
      remainder of each Milestone Payment is due upon completion of the
      Milestone.

3.    BATCHES FOR PHASE III CLINICAL SUPPLY:

      Price: US$ [******]. per Batch

      Notes - a)   Batch runs are ~30 doses of BMIPP of which 20 are shippable

              b)   Payment is due within 30 days of the date appearing on
                   Nordion's invoice.

 Pcdocs62680

<PAGE>

                           447 March Road               Tel: +1 613 592 2790
                           Ottawa, ON K2K 1X8           Fax: +1 613 592 6937
                           Canada                       www.mds.nordian.com

[MDS NORDION LOGO]
  Science Advancing Health

May 25, 2005

Molecular Insight Pharmaceuticals Inc.
160 Second Street
Cambridge, Massachusetts
02142
USA

Dear Sirs:

RE:   AMENDMENT #1 TO AGREEMENT BETWEEN MDS NORDION, A DIVISION OF MDS (CANADA)
      INC. (SUCCESSOR TO MDS NORDION INC.) AND MOLECULAR INSIGHT PHARMACEUTICALS
      INC. DATED THE 14th DAY OF JUNE, 2004

Reference is made to the agreement between MDS Nordion and Molecular Insight
Pharmaceuticals Inc., dated the 14th day of June 2004 (the "Agreement").

In consideration of $1.00 and other valuable consideration the receipt of
sufficiency of which is hereby acknowledged, the parties desire to extend the
terms of the Agreement.

Section 16.1 of the Agreement shall be amended in its entirety and shall read as
follows:

                "The term of this Agreement shall commence upon the Effective
                Date, and unless terminated earlier pursuant to this Agreement,
                shall expire on December 31, 2006."

All other terms and conditions in this Agreement shall remain in full force and
effect.

The foregoing amendment shall be effective as of the date first written above.

If you agree with the foregoing, please execute this agreement in the space
provided below.

Sincerely,

                                          We agree this 25th day of May, 2005
MDS NORDION                               MOLECULAR INSIGHT PHARMACEUTICALS INC.

Per: /s/ Gerry Vantellingen               Per: /s/ John E. McCray
     ----------------------------                 ------------------------------
     Name: Gerry Vantellingen                     Name: John E. McCray
     Title: Vice President, Sales                 Title: Chief Operating Officer